Get the Daily Brief
Latest Biotech News
Clinical proof for infectious-disease and oncology diagnostics platforms
Diasorin received FDA 510(k) clearance for a customizable syndromic GI pathogen multiplex PCR panel for its Liaison Plex system. The Liaison Plex Gastrointestinal Flex Assay detects 24...
Cancer drug pipeline signals: PI3Kα inhibitor expands beyond breast cancer
Relay Therapeutics reported Phase 2 efficacy data for zovegalisib (RLY-2608) in patients with PIK3CA-driven vascular anomalies, reporting a 60% volumetric response. The company framed the readout...
Regulatory and governance shakeups at FDA and trial contracting bottlenecks
The EMA proposed a centralized contract-support platform and template framework aimed at reducing clinical trial start-up delays in Europe. The regulator cited stakeholder feedback that contract...
IPO and funding: creating cash runway for clinical development
A wave of biotech financing activity highlighted Parabilis’ IPO plans and Create Medicines’ Series B round to support its in vivo CAR-T mRNA platform. Parabilis, fresh off a Regeneron...
AI-first scientific discovery pipelines enter peer-reviewed validation
A peer-reviewed Nature report describes Robin, a multi-agent system that automates end-to-end experimental biology workflows—spanning hypothesis generation, experiment design, interpretation, and...
Alzheimer’s and neurodegeneration: mechanistic targets emerge
Alzheimer’s disease researchers reported a molecular mechanism that regulates amyloid plaque formation by controlling BACE1 through the protein FBXW7α. The study, published in Cell Death Discovery...
Neonatal and pediatric care risk stratification improves with biomarkers and tools
Research aimed at improving neonatal and pediatric outcomes highlighted both biomarker discovery and clinical tool evaluation. One study in Pediatric Research compared early-onset sepsis...
Ebola response accelerates as outbreak status escalates
WHO declared the Bundibugyo ebolavirus outbreak in the Democratic Republic of Congo a public health emergency of international concern, citing confirmation of the species and a high positivity...
Regulatory actions and major approvals
The FDA cleared Diasorin’s customizable multiplex gastrointestinal pathogen PCR panel, expanding the Liaison Plex Flex menu with a 24-pathogen assay that labs can narrow or broaden using Flex...
AI acceleration in drug discovery and lab automation
Qiagen and Nvidia announced an integration of accelerated computing and Nvidia’s BioNeMo into Qiagen Digital Insights’ curated biomedical knowledgebases, targeting faster, evidence-linked AI...
Big money for modality buildout: deals and partnerships
Regeneron committed up to $2.3 billion to Parabilis Medicines to develop antibody–Helicon conjugates aimed at intracellular targets described as “historically undruggable.” The collaboration...
Clinical signal in rare vascular anomalies (PI3Kα inhibition)
Relay Therapeutics reported a Phase 2 efficacy signal for its isoform-selective PI3Kα inhibitor zovegalisib (RLY-2608) in patients with PIK3CA-driven vascular anomalies. The company said the trial...
Obesity pipeline: oral GLP-1 advances toward NDA
Vincentage Pharma reported that its once-daily oral small-molecule GLP-1 receptor agonist VCT-220 met primary endpoints in a pivotal Phase 3 trial in overweight or obese patients in China. The...
Funding for in-body CAR-T platforms
Create Medicines secured $122 million in a Series B to fund therapies that express CARs in patients’ cells using mRNA delivered via liquid nanoparticles. The company expects the cash to last...
Regulatory framework for individualized therapies
The FDA proposed a “Plausible Mechanism Framework” as an alternative evidence pathway for individualized and disease-targeted therapies when standard randomized trials may be impractical. BIO said...
Diagnostics expansion: GI syndromic testing and added pathogens
Diasorin’s Liaison Plex Flex assay was cleared for clinical use as a multiplex gastrointestinal pathogen PCR panel covering 24 bacteria, viruses, and parasites. The assay’s modular Flex software...
Healthcare governance: European trial contracting bottleneck
The European Medicines Agency proposed a centralized contract support platform and clinical trial contract templates to address persistent start-up delays across Europe. In its clinical trial...
Rare disease setbacks: Phase 3 misses and investor impact
BioMarin’s Phase 3 program for a rare inherited enzyme deficiency drug (from its Inozyme Pharma acquisition) missed the mark, meeting only one of two primary goals. The company’s results were...
Targeted cancer immunotherapy dealmaking
Regeneron struck a major research collaboration with Parabilis Medicines to develop antibody–peptide conjugates built around Parabilis’ Helicon platform. The pact centers on five undisclosed...
Clinical readouts and near-term pipeline value in oncology
Relay Therapeutics reported a Phase 2 efficacy signal for zovegalisib (RLY-2608) in patients with PIK3CA-driven vascular anomalies, delivering a 60% volumetric response that exceeded expectations...